Lots of news in the last few days. Sharing some

New Post Public Reply Private Reply Replies (2) Message Board
TechGuru
630
Lots of news in the last few days. Sharing some toughts:

In a way I am happy and, excuse me if I am selfish. I own a substantial number of shares and, currently, risking sleeping in the sofa for a considerable amount of time (until wife files for divorce and I go to the park bench ) in any slip of my tonge. But why I am happy?? I do extensive DD with any investment, with CYDY this meant reading several (understatement) papers and then, waiting for the clinical trials that would show that the drug was effective (or not). This is the name of the game. After investing in 2018 and continuing buying shares thereafter I could not possibly explain to myself why I got this so wrong. Back then there was talk of the BLA being submitted “soon”, and the no-adverse events new super-duper HIV drug approval was imminent.

For all these years I was wondering why the BLA had not been submitted and the drug approved. My initial reaction was that the FDA was stonewalling us as NP skillfully kept the carrot at the front of my face and, knowing that the drug works, I was all ears. I believed because this is what we are “trained” to do. You find a drug that works, you run trials, they are successful, you submit the BLA, the FDA approves, the drug sells, the SP goes higher, you make money and help patients … right???

But there was a big problem: the CRO (AMAREX) was incompetent, our CEO was a crook, inept/unable/unwilling at supervising the CRO and the BOD was nowhere to be seen.

I pose it that it would have been easier to do the right thing, conduct a proper trial and get Leronlimab to the goal, than to go through all this debauchery. There is a saying in my culture that says: It is easier being rich than poor, and better to be free than in the big house. A lot lost on the translation, but you get the point.

I forgot to say why I am happy: because now I can excuse myself for not being wrong about the science of our molecule; I am just not good at detecting charlatans.

But what is next?? Well, we have lost some time and money and are back to square one. We need to decide for which of the indications a clinical trial can be run the fastest and more economically (I am sure we have some trial protocols at the ready). Also, were and how we can get financing (partnerships?). The new CEO and board have little room to maneuver and taking the right decisions is a must.

At the end we will prevail and those buying these days will make a bundle.

Happy holidays to all, let's hope 2022 will bring all of us all we are wishing for.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 183

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 6

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading
Limina’s Amberflo Deal Makes AI Usage Visible at Scale

Updated Category News Views 32

Enterprise AI has created a billing fog, and Limina just bought itself a flashlight. Its merger with Amberflo, completed on October 30 and announced November 19, brings metering, cost attribution, and billing technology fully inside Limina’s data-governance platform. No price was disclosed, which is irritating but ordinary for a transaction involving companies that do...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 96

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 51

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
PTC Pushes Deeper Into Federal Product Development

Updated Category News Views 14

Federal engineering software is a miserable place to show up late, and PTC is plainly trying not to. Its November 19, 2026 expansion brings Windchill+ onto Microsoft Azure Government through PTC Cloud Services and introduces Onshape Government Federal for teams handling Controlled Unclassified Information. This is not a glamorous product refresh. It is a bid to remove the...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 60

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 67

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 34

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 54

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading

Top 5 Most Recently Viewed Articles

Home Depot Shines While the Market Treads Water—Notable Trends

Updated Category News Views 192

Market Overview There’s a certain chaos in the markets, right? U.S. stocks kicked off the week with a little bit of everything, a wild cocktail of ups and downs. The Dow, surprisingly, snagged a gain of over 100 points, closing up 0.27% at 48,935.82. But don’t get too comfy—NASDAQ took a hit, dropping about 0.39% to 22,538.28 while the S&P 500 stumbled down by 0.30%...

Continue Reading
Piston-Single Aircraft Inventory Shows Positive Trends Ahead

Updated Category News Views 106

Piston-Single Aircraft Inventory Shows Positive Trends Ahead In recent months, the aviation market has demonstrated notable resilience, particularly in the segment of used piston-single aircraft. Inventory data indicates a gradual recovery, showcasing a shift from the lows witnessed earlier this year. Despite a decline in overall inventory levels compared to last year,...

Continue Reading
K92 Mining Reports Significant Q2 Results and Expansion Plans

Updated Category News Views 215

K92 Mining Reports Strong Q2 Production Results K92 Mining Inc. (“K92”) (TSX: KNT; Other OTC: KNTNF) has recently shared its robust production performance for the second quarter. This impressive quarterly production total from the Kainantu Gold Mine showcases the upward trajectory of the company within the mining sector. Highlights of Q2 2025 Production The production...

Continue Reading
Explore Top Dividend Stocks to Consider Investing In

Updated Category News Views 105

Dividend Opportunities in Today's Market As the year unfolds, many investors are exploring alternatives to traditional fixed-income investments due to changing interest rates. Shifting focus to dividend-paying stocks can offer both steady income and the potential for capital appreciation. Realty Income (NYSE: O), Costco Wholesale (NASDAQ: COST), and Royal Caribbean...

Continue Reading
Braemar Hotels & Resorts Secures $115 Million Sale of The Clancy

Updated Category News Views 176

Braemar Hotels & Resorts Announces Sale Agreement for The Clancy DALLAS – Braemar Hotels & Resorts Inc. (NYSE: BHR) has officially entered into a significant agreement to sell its San Francisco property, The Clancy. This strategic move reflects the company's ongoing commitment to enhance its investment portfolio and maximize value for shareholders by divesting...

Continue Reading